Company reports all-time-high monthly cartridge sales for July with 60% year-on-year growth NEW YORK, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its highest-ever monthly cartridge sales for July 2025, with a record 519 boxes shipped, representing over... Read More

Company advanced efforts to secure U.S. FDA 510(k) clearance to advance on path towards planned U.S. market expansion beyond Forensic Use Only settings Fourth quarter sequential and year-on-year revenue growth of 16%, supported by increased demand for drug testing cartridges NEW YORK, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company... Read More

NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing and screening solutions, today announced that its management team will participate in the Sidoti Micro-Cap Virtual Conference being held on August 20-21, 2025. Presentation Details Date: Thursday, August 21, 2025 Time: 9:15 a.m.... Read More

Company anticipates fiscal fourth quarter sequential and year-on-year revenue growth of approximately 16% Company advanced efforts to secure U.S. FDA 510(k) clearance for planned U.S. market entry and strengthened global readiness through system upgrades and localization NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering... Read More

FDA response expected within six weeks; Company remains focused on 2025 U.S. expansion NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the submission of its Additional Information ("AI") response to the United States Food and Drug Administration... Read More

NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has secured a major contract with one of London's largest public transport operators, spanning 14 operational sites in greater London and employing over 4,400 staff. INBS's Intelligent Fingerprinting... Read More

Proceeds to Fund Completion of the Company’s 510k Filing with the U.S. FDA for its Fingerprint Drug Screening System NEW YORK, July 25, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced an agreement between the Company and several current warrant holders to exercise (or... Read More

Data confirms Company’s ability to detect trace sweat volumes at ultra-micro level System demonstrates resilience across diverse conditions NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful collection of new data that further reinforces... Read More

NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced a new global distribution agreement with SMARTOX®, a Texas-based leader in drug and alcohol screening services, to bring its SmarTest Patch drug detection product to international markets outside of the... Read More

NEW YORK, July 15, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the addition of the SmarTest® Patch to its portfolio of non-invasive drug testing solutions. The SmarTest Patch is an innovative wearable device, developed by SMARTOX®, that enables continuous drug... Read More

Data shows excretion of codeine in fingerprint sweat INBS’ System is viable option for non-invasive diagnostic testing NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing and screening solutions, today announced that it will present its Pharmacokinetic (“PK”) study data at the... Read More

With over 450 accounts across 24 countries, INBS continues to advance the evolution of drug screening technology NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, non-invasive drug screening solutions, today announced the success of its ongoing partnership with Spjotgard, an established distributor serving... Read More

NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that Managed Waste Service (“MWS”), a leading Australian waste management provider, plans to implement INBS’ Intelligent Fingerprinting Drug Screening System across its New South Wales operations,... Read More

AUSTIN, Texas, June 17, 2025 (GLOBE NEWSWIRE) -- via IBN – IBN , a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast delivers dynamic interviews with... Read More

SMARTOX has deployed over 50 of INBS’ Intelligent Fingerprinting Drug Screening Readers and facilitated over 7,000 screening tests, including more than 1,500 tests in 2024 alone Company continues to actively pursue FDA clearance in connection with planned expansion into broader U.S. markets in 2025 NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical... Read More

INBS to participate with U.S. distribution partner SMARTOX at RISE25, the leading U.S. conference on addiction, mental health, and justice innovation which draws over 7,000 attendees annually With over 450 active accounts across 24 countries, INBS continues to meet growing global demand for reliable, on-site drug testing solutions across the workplace, treatment, and justice sectors NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) --... Read More

Completion of 160 tests conducted in less than 90 minutes demonstrates a level of speed and efficiency beyond the limits of traditional testing approaches NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of a high-volume... Read More

Company surpasses 450 accounts across 24 countries as global demand for fingerprint drug testing surges NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc . (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced recent growth highlights across its global operations, driven by new account acquisitions,... Read More

20% sequential quarterly revenue growth and 91% year-over-year quarterly gross profit growth Continued momentum from recurring higher-margin cartridge sales now reaching 58% of total sales for the nine months ended March 31, 2025 35 new accounts and international growth during Q3 bring total active accounts to over 450 NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the... Read More

Arabic, Italian, and Spanish-language websites unlock commercial access to regions representing over 1.4 billion people Multilingual rollout aligns with product readiness and accelerates international sales pipeline development NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing... Read More

Company expands Intelligent Fingerprinting Drug Screening System multilingual capabilities to meet growing demand across Latin American Spanish-speaking markets Latin American drug screening market projected to reach USD 1.1 billion by 2030 Expansion is part of major multilingual Drug Screening System upgrade, targeting over 4 billion potential users worldwide NEW YORK, April 22, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio... Read More

NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has integrated Arabic as the second international language to its Intelligent Fingerprinting Drug... Read More

NEW YORK, March 28, 2025 (GLOBE NEWSWIRE) - - Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its participation as a gold sponsor at the 2025 National Drug and Alcohol Screening Association (NDASA) Conference and Trade Show, taking place from April 1 – 4 in Jacksonville, Florida. Daniel Brown,... Read More

INBS set to capitalize on growing Spanish Drug Testing Market, anticipated to reach $448 million by 2030 Major Spanish accounts currently require 1,000 drug testing cartridges per month NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has expanded... Read More

Company’s 6 th U.S. patent adds to comprehensive IP portfolio protecting its unique drug screening technology Patent protection strengthens Company’s competitive position as it prepares for planned entry into multi-billion dollar U.S. market in 2025 NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid,... Read More

NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today provided shareholders with a status update on the FDA clearance process for its Intelligent Fingerprint Drug Screening System, which remains on track for launch in the U.S. in 2025 targeting its opiate test... Read More

NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it expects to receive its sixth patent in the United States, which will strengthen the protection of the lateral flow technology core to its Intelligent Fingerprinting Drug Testing Solution. This... Read More

NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will participate in the iAccess Alpha Virtual Best Ideas Spring Conference 2025 on March 25 and 26, 2025. iAccess Alpha Virtual Conference Details: Date: March 25-26, 2025... Read More

NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the closing of its previously announced underwritten public offering of 1,500,000 shares of common stock at a public offering price of $2.00 per share of common stock, which included the full exercise of the... Read More

NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the pricing of its previously announced underwritten public offering of 1,304,348 shares of common stock at a public offering price of $2.00 per share of common stock, for gross proceeds of approximately $2.6... Read More

NEW YORK, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”) a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it is commencing an underwritten public offering of shares of its common stock. All of the shares of common stock are being offered by Intelligent Bio Solutions Inc. The offering is subject to market... Read More

Gross profit increase of 32.6% and 11-point gross profit margin increase driven by higher-margin cartridge sales Submitted FDA 510(k) and remain on track for planned expansion into multi-billion dollar U.S. market in 2025 Added strategic partnerships, increasing visibility across the Asia-Pacific Region and the U.S. Secured 19 accounts during quarter, adding to 400+ active customer accounts in 19 countries NEW YORK, Feb. 13,... Read More

NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today issued a letter to shareholders from Harry Simeonidis, President and CEO, reflecting on a year of growth in 2024 and its strategic path forward into the multi-billion dollar U.S. market in 2025. Dear Shareholders,... Read More

Avon Freight Group selects INBS’ fingerprint drug testing for three UK sites, reinforcing workplace safety and efficiency INBS surpasses 400+ accounts in 19 countries, targeting aggressive U.S. expansion in 2025 following FDA 510(k) submission UK drug testing market projected to hit $453M by 2030, positioning INBS as a scalable, cost-effective industry leader NEW YORK, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio... Read More

Gross profit expected to surge by 32.6% Unaudited revenue of $0.61 million for fiscal Q2 and $1.48 million for the six months ended December 31, 2024 Higher-margin cartridge sales driving profitability and long-term growth Expanding U.S. and international market presence with FDA submission and strategic partnerships NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the... Read More

NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced plans for a major upgrade to its Intelligent Fingerprinting Drug Screening System. The system upgrade will support multiple languages spoken across North and South America, Europe, Asia Pacific and the... Read More

Quantum Traffic Management transitions from saliva and urine testing to non-invasive, in-house fingerprint sweat-based drug screening Most recent client added to INBS’s portfolio of more than 400 accounts across the globe, as the Company plans entry into the US market in 2025 NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company... Read More

NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the strengthening of its foothold throughout Europe and the Middle East through its partnership with IVY Diagnostics Srl (“IVY Diagnostics”). As a key distributor, IVY Diagnostics is playing an integral... Read More

NEW YORK, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that Princebuild, a leading construction firm with seven sites and operations spanning six key divisions, has adopted INBS’ Intelligent Fingerprinting Drug Screening System. Princebuild has made a... Read More

NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the submission of its 510(k) premarket notification to the US Food and Drug Administration (FDA) for... Read More

NEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it will host a virtual fireside chat with Harry Simeonidis, President & CEO and Spiro Sakiris, CFO at 4:30 p.m. ET on December 11, 2024. During the event, management will discuss the Company's recent... Read More

Intelligent Fingerprinting Drug Screening System on path to FDA 510(k) submission, expected in the fourth calendar quarter of 2024 INBS will include data from recent PK study alongside results of method comparison study in 510(k) submission NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid,... Read More

NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will present at the upcoming Noble Capital Markets’ 20 th Annual Emerging Growth Equity Conference on December 3-4, 2024, in Boca Raton, FL. Noble Capital Markets’ 20 th Annual... Read More

PK Study Successfully Demonstrates that Fingerprint Sweat Provides Reliable Sample for Drug Detection FDA 510(k) Clearance Would Enable the Introduction of INBS’ Technology to the US in 2025 NEW YORK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology... Read More

Quarterly revenue increased 10% year-on-year and 20% quarter-on-quarter, marking four consecutive quarters of year-on-year growth Higher-margin, recurring cartridge revenue surpassed reader revenue as primary driver Completed in-clinic portion of FDA 510(k) clinical study plan, on track to submit to FDA by year-end Expanded distribution network in Saudi Arabia Initial review of PK study results show fingerprint sweat... Read More

NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced a strategic partnership with B2i Digital to launch an investor-focused marketing campaign. B2i Digital will employ advanced digital marketing strategies to raise awareness of INBS’ patented drug... Read More

Unaudited quarterly revenue increased 10% year-on-year and 20% quarter-on-quarter Higher-margin, recurring cartridge revenue expected to surpass reader revenue as primary driver Expanded distribution network in Saudi Arabia NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing... Read More

NEW YORK, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company offering non-invasive, rapid testing solutions, today announced that its customer Mount Anvil, one of London's most respected property developers, has celebrated its one-year anniversary of enhanced workplace safety after integrating INBS’ Intelligent Fingerprinting Drug Screening... Read More

New York, New York--(Newsfile Corp. - October 16, 2024) - Intelligent Bio Solutions Inc. (NASDAQ: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will present in the upcoming LD Micro Main Event XVII on October 28-30, 2024, in Los Angeles. LD Micro Main Event XVII Dates: October 28-30, 2024 Location: Luxe... Read More

NEW YORK, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company offering non-invasive, rapid testing solutions, today announced the addition of Pyrotek Pty Ltd (“Pyrotek”), to its customer base. Pyrotek is a global leader in engineering solutions. By adopting INBS’ Intelligent Fingerprinting Drug Testing Solution across its Australian branches,... Read More

NEW YORK, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its distribution partnership with Spirit Group, an Australian, Indigenous-owned marketing and consulting agency, with prominent clients across a wide range of industries, including mining, transportation... Read More

NEW YORK, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the addition of GPS Marine, a leading provider of marine construction and logistics services, to its growing number of customer accounts. GPS Marine delivers critical maritime services across the UK’s... Read More

NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of in-clinic testing proposed to the FDA earlier this year in the Company’s clinical study plan. The clinical studies are a key element of the Company's 510(k) submission,... Read More

NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that Thanet Earth, the UK’s largest greenhouse complex, has adopted its Intelligent Fingerprinting Drug Screening System for in-house drug testing. “We are thrilled to partner with Intelligent... Read More

Fourth-quarter revenue of $0.73 million, up 64% year-over-year Full-year revenue of $3.11 million, up 148% year-over-year As of June 30, 2024, the Company had $6.30 million in cash NEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, announced its financial results for... Read More

NEW YORK, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a leader in non-invasive drug testing technology, today announced that its management team will participate in the Sidoti Small-Cap Virtual Conference being held on September 18-19, 2024. Presentation Details Date: Thursday, September 19, 2024 Time: 2:30 p.m. Eastern Time Registration/Webcast Link For more... Read More

2024 unaudited revenue growth for the fiscal fourth quarter and full year of approximately 64% and 148% year-over-year, respectively NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced preliminary unaudited revenue results for the fiscal fourth quarter... Read More

NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its progress toward completion of the clinical study plan required for its FDA 510(k) submission. In August 2024, INBS announced its partnership with CenExel to perform the method comparison study as... Read More

NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ: INBS) (“INBS” or the “Company”), a leader in non-invasive drug testing technology, today announced significant growth in its customer employee base, reporting a 118% fiscal year-over-year increase in the estimated total number of employees across its customer base. As of June 30, 2024, the estimated number of employees within INBS’ global... Read More

NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ: INBS) (“INBS” or the “Company”), a leading innovator in non-invasive drug testing technology, today announced the installation of over 1,000 Intelligent Fingerprinting Drug Screening Readers with customers as of June 30, 2024. This achievement marks a significant milestone for INBS, underscoring the growing demand for the Company’s advanced... Read More

NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ: INBS) provides an overview of the increasing prevalence of on-the-job drug use across critical sectors such as construction, manufacturing, transport and warehousing, mining, and automotive. As the need for robust drug testing solutions intensifies, we believe that our company is positioned to lead the way in providing innovative,... Read More

NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its partnership with CenExel , a nationwide clinical research site network, to perform a method comparison clinical study as part of the Company’s FDA 510(k) clinical study plan. The Company’s method... Read More

NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced QabasTech (“Qabas”) as its exclusive distributor in Saudi Arabia. This partnership marks further growth for INBS in the country, aligning with its ambitious infrastructure projects and commitment to... Read More

NEW YORK, July 18, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of biocompatibility testing of its Intelligent Fingerprinting Drug Screening System, a pivotal phase in the clinical study plan required for FDA 510(k) regulatory clearance. The... Read More

NEW YORK, July 09, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the addition of several key accounts in the UK manufacturing sector. This announcement follows recent successes in the warehouse and logistics , transport and infrastructure , and retail sectors as the... Read More

NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of the in-clinic portion of its pharmacokinetic (PK) study, a core component of the Company's clinical study plan for its 510(k) pathway for regulatory approval. Dosing and... Read More

NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the expansion of its customer network within the UK retail sector. This includes the adoption of INBS' Intelligent Fingerprinting Drug Screening System by three prominent UK retailers, among the largest... Read More

NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it has successfully signed two new major customer accounts within the UK warehouse and logistics sector within the past three months. These accounts employ more than 15,000 individuals at more than... Read More

NEW YORK, June 18, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it is entering the next phase of its planned 510(k) submission to the FDA. The Company has successfully completed subject screening for its Pharmacokinetic (PK) Study and will begin dosing and... Read More

NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the implementation of a strategic and comprehensive reorganization and productivity plan to support the Company’s global growth initiatives. As the Company approaches several growth initiatives globally,... Read More

NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the addition of a major European transport and infrastructure solutions provider to its growing number of accounts. The company is using INBS' Intelligent Fingerprinting Drug Screening System to monitor... Read More

NEW YORK, June 06, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will participate in the Sidoti Small-Cap Conference being held virtually June 12-13, 2024. Presentation Details Date: Wednesday, June 12, 2024 Time: 4:00 p.m. Eastern Time... Read More

NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful recruitment and commencement of screening for subjects in its pharmacokinetic (PK) study, a critical component of the Company's FDA 510(k) regulatory pathway for clearance. Harry... Read More

NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today unveiled key performance indicators from its United Kingdom operations. These indicators have contributed to the Company’s growth as the drug screening industry continues to combat drug test cheating and searches... Read More

NEW YORK, May 17, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful exhibition of its Intelligent Fingerprinting Drug Screening Solution at The Health & Safety Event 2024, the United Kingdom’s largest annual technology showcase exhibiting products and... Read More

Year-over-year revenue increased 80% for the fiscal third quarter and 193% for the nine months ended March 31, 2024 Cash and cash equivalents as of March 31, 2024, was $9.40 million Commenced FDA 510(k) clinical studies plan with Cliantha Research and remains on track for planned submission by the end of 2024 and planned entry into the US in 2025 Secured 26 new customer accounts throughout the quarter, representing a... Read More

NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced preliminary unaudited revenue results for the fiscal third quarter and nine months ended March 31, 2024. The Company expects approximate unaudited revenue of $0.82 million for the three months ended... Read More

NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (“INBS” or the “Company”) (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the broadening of the intellectual property portfolio of its wholly owned subsidiary, Intelligent Fingerprinting Limited, with the grant of a new European patent with unitary effect for its... Read More

NEW YORK, March 26, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("INBS" or the "Company") (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that President and CEO, Harry Simeonidis, and CFO, Spiro Sakiris, are scheduled to present at the LD Micro Invitational XIV Investor Conference to be held on April 8-9, 2024 in New York City. LD Micro... Read More

NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("INBS" or the "Company") (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the closing of its previously announced private placement priced at-the-market under Nasdaq rules of 2,223,333 shares of common stock (or pre-funded warrants in lieu thereof), Series H-1 warrants to... Read More

NEW YORK, March 11, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("INBS" or the "Company") (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that on March 8, 2024, it entered into securities purchase agreements with several healthcare-focused institutional and accredited investors to issue, in a private placement priced at-the-market under... Read More

NEW YORK, March 01, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it will present at the Emerging Growth Conference on March 6, 2024. INBS will provide an update on the Company’s growth and financial performance in 2023, among other topics. Spiro Sakiris, INBS’... Read More

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("INBS" or the "Company") (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its partnership with Cliantha Research , a full-service Clinical Research Organization (CRO), to perform a pharmacokinetic (PK) study forming part of the Company’s FDA 510(k) clinical study plan. The... Read More

NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("INBS" or the "Company") (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that on February 13, 2024, it received written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq... Read More

Year-over-year revenue increased 114% for the fiscal second quarter and 337% for the six-months ending December 31, 2023 Expanded into New Zealand market and increased market share in existing regions NEW YORK, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("INBS" or the "Company") (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced... Read More

NEW YORK, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced an agreement between the Company and several current warrant holders to exercise certain existing Series E Warrants (the “Existing Warrants”) to purchase up to an aggregate of 606,064 shares of common... Read More

NEW YORK, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced preliminary unaudited revenue results for fiscal Second Quarter and six months ended December 31, 2023. The Company expects approximate unaudited revenue of $1.56 million for the six months ended... Read More

Customers identify in-house control, project flexibility, productivity, and cost reductions as key business benefits of fingerprint sweat-based drug testing Construction and manufacturing firms replace traditional urine and oral fluid drug tests with more hygienic and dignified Intelligent Fingerprinting Drug Screening System - disrupting workplace testing market NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio... Read More

Intelligent Fingerprinting to be used for in-house drug testing, enabling full testing control to support new James Jones drug and alcohol testing policy Portable Intelligent Fingerprinting system easily covers testing needs across all remote locations and allows in-house ownership NEW YORK, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company... Read More

NEW YORK, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“Intelligent Bio Solutions” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it will effect a 1-for-12 reverse split of its common stock, that will become effective at 5:00 pm (Eastern Time) on January 26, 2024. Trading of the Company's common stock on... Read More

Construction logistics, security, and support specialist selects Intelligent Fingerprinting Drug Screening System to simplify and speed up workplace drug testing for its 450 employees and contractors “By using fingerprint drug testing, I no longer have to take people off a project for half a day for screening – we can conduct the tests there and then” – Ruth Trant, SHEQ & Assurance Director, DGP Plc NEW YORK, Jan. 22, 2024... Read More

NEW YORK, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that Robinson Brothers , one of the UK’s largest independent chemical manufacturers, is now using its revolutionary portable Intelligent Fingerprinting Drug Screening System to support its drug and... Read More

NEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (“INBS” or the “Company”) (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it has received National Association of Testing Authorities (NATA) accreditation for its Intelligent Fingerprinting Drug Screening Solution . NATA accreditation is acknowledged nationally and... Read More

Intelligent Fingerprinting Drug Screening System is expected to reduce P&O Ferries’ overall drug testing costs by 90% Easy-to-use, hygienic fingerprint sweat test improves the testing experience for P&O Ferries employees from previous urine method NEW YORK, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid,... Read More

NEW YORK, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that Titan Cranes and Rigging Pty Ltd. ("Titan") has adopted the Company's unique Intelligent Fingerprinting Drug Screening System . Since 2001, Titan has secured its spot as Australasia’s leading... Read More

NEW YORK, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it will present at the Emerging Growth Conference on December 7, 2023. The Company will provide insight into the Company’s unique proprietary Intelligent Fingerprinting Drug Screening System , among... Read More

NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that successful Australian civil construction entity, State Road Constructions ("State Road"), has selected its proprietary Intelligent Fingerprinting Drug Screening System as its workplace drug... Read More

First fiscal quarter revenue and government support income increased 191% year-over-year and 88% sequentially due to strong organic growth and execution of expansion plans Increased market share organically in existing markets and entered South American market Advanced plans for expansion into the U.S. market Completed critical development milestone in plans to add new assays for ketamine and tramadol to the Intelligent... Read More

NEW YORK, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its expansion into the New Zealand market, representing a significant milestone in the Company’s growth strategy for its Intelligent Fingerprinting Drug Screening System . Drug-related harm in New... Read More

VKVP Haulage adopts Fingerprint Drug Screening System to help drive proactive drug testing policy Auctus Management Group successfully completes 25,000 tests using the Company’s Intelligent Fingerprinting Drug Screening System NEW YORK, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing... Read More

NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the closing of its previously announced underwritten public offering of units (the “Units”) for gross proceeds of approximately $4.378 million prior to deducting underwriting discounts and commissions and offering... Read More

NEW YORK, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the pricing of an underwritten public offering of units (the “Units”) for gross proceeds of approximately $4.0 million. Ladenburg Thalmann & Co. Inc. is acting as the sole bookrunning manager for the offering. The... Read More

NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its Intelligent Fingerprinting Drug Screening business has obtained recertification for the latest ISO 13485: 2016 harmonized quality management system standard for the medical device industry. The... Read More

NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful debut of its Intelligent Fingerprinting Drug Screening System at the 2023 Workplace... Read More

NEW YORK, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of a key development milestone in its plans to add ketamine and tramadol to its Intelligent Fingerprinting Drug Screening System. New assays for testing both drugs have passed... Read More